A stool-based enema composed of a broad variety of microbes (RBX2660, Rebiotix/Ferring) was up to 84% effective in reducing recurrent emClostridioides difficile/em infection in a study of more than 720 adults with rCDI. br /p /p

Following a period of bearish conditions, investors are anxiously awaiting the next big rally. A return to normal levels would help revitalize investor portfolios and confidence following a difficult month for the markets. However, the return to bullish conditions may come sooner than many may believe –especially for those companies that navigated the situation wisely. […]

Tweetable abstract Treating Clostridioides difficile infection with miRNAs alone or combined with live biotherapeutic products may augment therapeutic efficacy and help counteract drug resistance in the future.

TNP-2198, a stable conjugate of a rifamycin pharmacophore and a nitroimidazole pharmacophore, has been designed, synthesized, and evaluated as a novel dual-targeted antibacterial agent for the treatment of microaerophilic and anaerobic bacterial infections. TNP-2198 exhibits greater activity than a …

An investigational oral microbiome treatment was 70% more effective than placebo in preventing CDI recurrence within 8 weeks of treatment. https://t.co/9o8lQcFGkw @DrPaulGastro #cdiff— Gastro & Endo News (@gastroendonews) February 17, 2022

Original Article from The New England Journal of Medicine — SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection

An experimental three-day therapy that involves introducing Firmicutes spores into the gut may reduce the risk of Clostridium difficile reinfection by nearly 70%, a phase III trial shows. The treatment, known as SER-109, appeared to be more effective in patients under 65, which the US researchers say is “clinically important” given their increased risk of recurrent disease and hospital readmission. Most patients had a sustained clinical response 'out to about six months', researchers say.

Big pharma and investors focusing on other segments despite the need for new therapeutics

Clostridium difficile is an important zoonotic intestinal pathogen, which is widely present in humans and a variety of animals. The ST11 type C. difficile is one of the most widespread and harmful subtypes in the world. As a large country in pig farming, China lacks efficient methods f …

In this phase 2a study, ten of ten patients achieved SCC, demonstrated favorable pharmacokinetics, minimal adverse events, and beneficial microbiome and bile acids results. These results support continued clinical development.

Acurx Pharmaceuticals, Inc. announced today that results of its positive Phase 2a clinical trial have been published in Clinical Infectious Diseases.

Bacteriophages represent a promising option for the treatment of Clostridioides difficile (formerly Clostridium difficile) infection (CDI), which at present relies on conventional antibiotic therapy. The specificity of bacteriophages should prevent dysbiosis of the colonic microbiota associated with …

Join us to tackle one of the most important challenges of our time: antimicrobial resistance (AMR)! The Castagner Lab is developing non-antibiotic approaches against the Clostridioides difficile pa…

4D Pharma has programs for treating irritable bowel syndrome (IBS) but also for cancer. 4D researchers have found, for example, that short chain fatty acids from M. massiliensis enhance the production of effector cytokines in CD8+ cells. Even more interestingly, 4D’s MRx0518 live biotherapeutic, is currently under investigation as an adjuvant treatment (with Keytruda) for a variety of cancers.

Adjuvant combinations may enhance or broaden the expression of immune responses to vaccine antigens. Information on whether established Alum type adjuvants can be combined with experimental CD1d ligand adjuvants is currently lacking. In this study, we used a murine Clostridioides difficile im …

The Investor Relations website contains information about Seres Therapeutics's business for stockholders, potential investors, and financial analysts.

Saccharomyces boulardii is a yeast clinically used for treating various symptoms of gastrointestinal dysbiosis. Despite their genomic relatedness, S. boulardii has a distinctive cell wall oligosaccharide composition compared to baker's yeast S. cerevisiae, such as higher mannan content. Here we expl …

/PRNewswire/ -- MyBiotics Pharma Ltd, a clinical stage microbiome therapeutics company, today announced the successful completion of Phase I clinical trial of...

Investigational oral live microbiome therapeutic superior to placebo in patients with three or more episodes of C. difficile infection

/PRNewswire/ -- MyBiotics Pharma Ltd, a clinical stage microbiome therapeutics company, today announced the successful completion of Phase I clinical trial of...

NTCD-M3, which researchers are readying to phase III clinical trials, was the subject to a separate preclinical study by the US Department of...

Increasing patient access to fecal microbiota transplantation.

Quick Take Video Summary from The New England Journal of Medicine — Oral Microbiome Therapy for Recurrent C. difficile Infection

Phase III trial showed 'two-pronged' approach worked, regardless of age, antibiotic type

Only 12% of SER-109 treated patients had a recurrence, compared to 40% of the placebo group.

Phase 3 data from Seres Therapeutics on SER-109, its experimental oral microbiome therapeutic, showed it was superior to placebo in reducing C. difficile infection recurrence.